Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Angle kappa: does it matter in multifocal intraocular lens surgery?

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal I

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 09:52

Venue: Auditorium A

First Author: : R.Dubey AUSTRALIA

Co Author(s): :    A. Haider   P. Versace                 

Abstract Details

Purpose:

Halos and glare are the most common patient complaints following multifocal intraocular lens implantation. There has been speculation that negative symptoms may be reduced with improved centration of the intraocular lens.We looked to analyse the relationship between angle kappa and symptoms of glare and halo for two different multifocal intraocular lenses.

Setting:

Ophthalmology surgery unit in Sydney, NSW, Australia

Methods:

A single surgeon case series of 85 patients and 176 eyes all implanted with either Oculentis Mf20( 88 eyes) or Zeiss Trifocal (79) intraocular lens All patients were asked to grade their glare and halo symptoms using a questionnaire and proprietary simulation software. Angle kappa measurements were undertaken using Orbscan,.ATLAS topographer and AcuTarget HD

Results:

The Oculentis Mf20 cohort reported significantly fewer glare and halo symptoms than the Zeiss Trifocal, and were more satisfied with night driving. Both cohorts were found to have significantly higher dissatisfaction ratings when measured angle kappa was greater than 3 degrees.

Conclusions:

There is an association between large angle kappa and degree of negative symptoms following implantation of multifocal intraocular lenses. Surgeons should consider alternative lens choices and counsel patients appropriately.

Financial Disclosure:

NONE

Back to previous